What Gives Patients and Loved Ones Hope?

If metastatic breast cancer no longer responds to a given therapy, finding out what targetable mutations a patient has may guide the next steps for treatment, an expert said.

CURE® editors discuss data from the European Society of Medical Oncology Annual Congress, and how it could lead to new therapies being approved.

Datopotamab deruxtecan elicited encouraging responses in patients with heavily pretreated non–small cell lung cancer harboring actionable genomic alterations.

The Welireg-Cabometyx treatment combination demonstrated anti-tumor activity for some patients with clear cell renal carcinoma, according to a phase 2 trial.

An expert explained the different treatment options for patients with estrogen receptor-positive, HER2-negative breast cancer that has recently been diagnosed or has recurred.

An expert explained how next-generation sequencing can help patients with metastatic breast cancer understand their disease and available treatment options.